Verseon

Verseon Corporation is an American pharmaceutical company based in Fremont, California. It was founded in 2002 by Adityo Prakash, Eniko Fodor, and David Kita, who created the company's proprietary physics-based computational drug discovery platform.[1] In 2017 Verseon's drug discovery platform was named as one of the Financial Times' '50 Ideas to Change the World'.[2] High-profile members of Verseon's scientific advisory board include Steven Chu, Nobel Prize-winning physicist and former US energy secretary, and John Leonard, former Chief Scientific Officer of AbbVie Inc.[3]

Drug discovery platform

Verseon's drug discovery platform is able to create a library of virtual drug-like compounds, as well as accurately model ligand/receptor interactions in silico, and so predict how drug-like molecules will interact with disease proteins.[4] This results in large number of novel compounds with higher affinity for their targets.[1] This kind of physics-based molecular modelling platform could be a new way for the pharmaceutical industry to discover drugs.[3] Currently, most drugs are discovered using the high-throughput screening method.[5]

Stock market listing

Verseon completed a £300m stock exchange listing on the London Alternative Investment Market (Aim) in 2015,[6] with backing from several major UK investors, including Neil Woodford.[7]

In December 2019, after obtaining stockholder approval, Verseon returned to private ownership.[8]

Drug pipeline

Verseon is currently pursuing drug programs in anticoagulation,[9] diabetic macular edema,[10] hereditary angioedema,[11] and oncology (solid tumors). Preclinical tests have found that Verseon's novel anticoagulant compounds prevent thrombosis while preserving platelet function, meaning they are associated with significantly lower bleeding times than other currently approved anticoagulants dabigatran, argatroban or apixaban.[12] None of Verseon's compounds have yet been validated in clinical trials.

References
  1. "Bio-IT World". www.bio-itworld.com. Retrieved 2017-10-05.
  2. Palmer, Maija (2017-10-02). "Readers' suggestions for 50 ideas to change the world". Financial Times. Retrieved 2017-10-05.
  3. Ward, Andrew (2016-04-01). "Big pharma seeks digital solution to productivity problem". Financial Times. Retrieved 2017-10-05.
  4. Goodman, Michael (June 2016). "In Silico Drug Design: Finally Ready for Prime Time?" (PDF). In Vivo. Retrieved 5 October 2017.
  5. Szymański, Paweł; Markowicz, Magdalena; Mikiciuk-Olasik, Elżbieta (2011-12-29). "Adaptation of High-Throughput Screening in Drug Discovery—Toxicological Screening Tests". International Journal of Molecular Sciences. 13 (1): 427–452. doi:10.3390/ijms13010427. ISSN 1422-0067. PMC 3269696. PMID 22312262.
  6. "Verseon Corporation - London Stock Exchange". www.londonstockexchange.com. Retrieved 2017-10-05.
  7. "Subscribe to read". Financial Times. Retrieved 2017-10-05.
  8. "Result of Special Shareholder Meeting". www.londonstockexchange.com. Retrieved 2019-12-18.
  9. Report, Science World (2016-12-12). "Blood Clot Treatment Found By Researchers At Verseon Corporation". Science World Report. Retrieved 2017-10-05.
  10. "Eyewire Today | Verseon to Reveal Preclinical Results on Novel Drug Candidates in Diabetic Macular Edema Program at BIO 2017". Eyewire Today. 2017-06-12. Retrieved 2017-10-05.
  11. "Verseon developing oral treatment for HAE". HAEi - International Patient Organization for C1 Inhibitor Deficiencies. Retrieved 2017-10-05.
  12. Sivaraja, Mohan; et al. (2016-12-02). "Novel Class of Direct Thrombin Inhibitors Prevent Thrombosis By Inhibiting Fibrinogen Cleavage While Preserving Platelet Function". Blood. 128 (22): 3834–3834. ISSN 0006-4971.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.